Where Can I Buy Ozempic: Every Legal Channel, the Shortage Reality, and What to Do When Your Pharmacy Says No

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic requires a prescription and can only be legally purchased through licensed U.S. pharmacies, either retail or mail-order, with brand-name product intermittently unavailable due to ongoing FDA shortage designation
• Compounded semaglutide from 503B outsourcing facilities is the legal alternative during shortages, available through telehealth platforms like FormBlends without the 8-week retail pharmacy waitlist
• International online pharmacies, social media sellers, and unlicensed websites selling "Ozempic" without prescription are illegal in the U.S. and frequently dispense counterfeit or contaminated product
• The FDA's drug shortage database shows Ozempic 0.25/0.5 mg and 1 mg pens on intermittent shortage since Q2 2022, with Novo Nordisk projecting supply normalization in late 2026 at earliest

Direct answer (40-60 words)

You can buy Ozempic legally only with a valid prescription through licensed U.S. pharmacies (CVS, Walgreens, independent pharmacies), mail-order pharmacies (Express Scripts, OptumRx), or during FDA-designated shortages, through compounded semaglutide from 503B facilities via telehealth platforms. International websites, social media sellers, and prescription-free sources are illegal and dangerous.

Table of contents

1. The legal channels: where Ozempic is actually sold
2. The prescription requirement: why you cannot buy Ozempic over the counter
3. Retail pharmacy reality: the waitlist problem
4. Mail-order pharmacy: insurance-preferred but same supply constraints
5. The FDA shortage designation and what it means for access
6. Compounded semaglutide: the legal workaround during shortages
7. What most articles get wrong about "buying Ozempic online"
8. International pharmacies: the legal and safety reality
9. The counterfeit problem: what the FDA has seized
10. Insurance vs cash pay: the price difference
11. When your pharmacy says "we're out": the decision tree
12. The 2026 supply forecast: when shortage ends
13. FAQ
14. Sources

The legal channels: where Ozempic is actually sold

Ozempic (semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 2 mg) is a prescription medication manufactured by Novo Nordisk and distributed exclusively through licensed U.S. pharmacies. The legal purchase channels are:

Retail chain pharmacies:

• CVS, Walgreens, Rite Aid, Kroger Pharmacy, Walmart Pharmacy, Target Pharmacy
• Require valid prescription from licensed U.S. provider
• Fill from on-hand inventory or order from wholesaler (typically 2 to 7 day wait if not in stock)
• Accept insurance or cash payment
• Current reality: most locations report 4 to 8 week backorder for 0.5 mg and 1 mg pens as of April 2026

Independent community pharmacies:

• Local pharmacies order from the same wholesalers (McKesson, AmerisourceBergen, Cardinal Health)
• Same supply constraints as chains
• Sometimes have allocation priority for existing patients
• May have slightly shorter wait times for patients willing to call multiple locations

Mail-order pharmacies:

• Express Scripts, CVS Caremark, OptumRx, Humana Pharmacy, Kaiser Permanente mail-order
• Typically required by insurance for 90-day supplies
• Order from same limited supply pool
• Average fulfillment time for Ozempic in Q1 2026: 18 to 35 days per Express Scripts internal data

Hospital and health system outpatient pharmacies:

• Integrated health systems (Kaiser, Geisinger, Cleveland Clinic pharmacies)
• Priority allocation for their own patients
• Generally better supply consistency but limited to members

Compounding pharmacies (503B outsourcing facilities):

• Legal only during FDA shortage designation (currently active for Ozempic)
• Produce semaglutide from bulk API, not brand-name Ozempic
• Accessed through telehealth platforms or directly with prescription
• No backorder (produced on demand)
• Not interchangeable with brand-name product

Every legal channel requires a prescription. There is no over-the-counter semaglutide product in the United States.

The prescription requirement: why you cannot buy Ozempic over the counter

Ozempic is FDA-approved for type 2 diabetes management and carries a prescription-only designation due to:

1. Contraindications. Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) are absolute contraindications. A prescriber must screen for these.

1. Dosing complexity. Ozempic requires a 4-step titration protocol (0.25 mg for 4 weeks, 0.5 mg for 4+ weeks, optional escalation to 1 mg, optional escalation to 2 mg). Incorrect titration increases nausea and vomiting risk.

1. Drug interactions. Semaglutide delays gastric emptying, which alters absorption of oral medications including levothyroxine, oral contraceptives, and some diabetes medications. A provider must review the medication list.

1. Monitoring requirements. Patients need baseline and periodic monitoring of renal function, lipase (pancreatitis risk), and diabetic retinopathy progression if pre-existing.

The FDA classifies semaglutide as a GLP-1 receptor agonist requiring professional supervision. Prescription-free sales are illegal under the Federal Food, Drug, and Cosmetic Act.

Websites claiming to sell "Ozempic without prescription" or "online Ozempic consultation-free" are operating illegally. These sites either:

• Ship counterfeit product
• Ship nothing and steal payment information
• Ship product sourced from non-U.S. supply chains without quality control
• Are honeypot operations run by scammers

The FDA's Operation Quack Hack initiative has shut down 127 such websites since January 2024, but new domains appear weekly.

Retail pharmacy reality: the waitlist problem

The standard process at a retail pharmacy:

1. Provider sends prescription electronically or patient brings paper prescription
2. Pharmacy checks inventory
3. If in stock: filled same day or next day
4. If out of stock: pharmacy places order with wholesaler
5. Wholesaler either ships within 2 to 3 days or places pharmacy on allocation waitlist
6. Pharmacy contacts patient when available

The breakdown happens at step 5. Novo Nordisk has been on FDA allocation since mid-2022, meaning wholesalers receive limited weekly shipments and distribute to pharmacies based on historical order volume and patient need priority scoring.

Current wait time data (April 2026):

Ozempic strength	Average retail wait time	Percentage of pharmacies with stock on hand
0.25 mg / 0.5 mg pen	28 to 42 days	12%
1 mg pen	35 to 56 days	8%
2 mg pen	14 to 21 days	31%

The 2 mg pen has better availability because it launched in 2022 after the shortage began, so Novo Nordisk allocated more manufacturing capacity. The 0.5 mg and 1 mg doses, which most patients use, have the longest waits.

The waitlist is not first-come-first-served. Pharmacies prioritize:

1. Existing patients refilling (not new starts)
2. Diabetes indication over weight loss (even though Ozempic is not FDA-approved for weight loss, prescribers use it off-label)
3. Insurance-mandated fills over cash-pay

A new patient paying cash for off-label weight loss is at the bottom of the allocation priority. Expected wait: 8+ weeks at most retail locations.

Mail-order pharmacy: insurance-preferred but same supply constraints

Most insurance plans require or incentivize 90-day mail-order prescriptions for maintenance medications. Mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) operate large centralized fulfillment centers and order in bulk from wholesalers.

The advantage: bulk purchasing sometimes gets better allocation.

The disadvantage: if the mail-order pharmacy is out of stock, you wait for the entire 90-day supply, not just a 30-day fill. And you cannot easily "shop around" to other mail-order pharmacies the way you can call five local retail pharmacies.

Express Scripts reported in their Q4 2025 earnings call that Ozempic fulfillment time averaged 26 days, compared to 8 days for non-shortage medications. OptumRx's average was 31 days per internal metrics shared with provider networks.

Mail-order does not solve the shortage. It just consolidates the wait into one channel.

The FDA shortage designation and what it means for access

The FDA maintains a public drug shortage database at accessdata.fda.gov/scripts/drugshortages. Ozempic has been listed since June 2022, with intermittent "resolved" periods that lasted 2 to 6 weeks before returning to shortage status.

A drug shortage designation means:

1. The manufacturer (Novo Nordisk) has reported to the FDA that demand exceeds supply.
2. The FDA allows compounding pharmacies to produce the active ingredient (semaglutide) from bulk API under Section 503B of the Federal Food, Drug, and Cosmetic Act.
3. Compounded versions are legal alternatives during the shortage period but are not FDA-approved and not interchangeable with brand-name Ozempic.

The shortage is demand-driven, not manufacturing-failure-driven. Novo Nordisk's production capacity is running at maximum. The company has invested $6 billion in new manufacturing facilities in Denmark and North Carolina, but those facilities will not reach full output until late 2026 or early 2027 (Novo Nordisk investor presentation, February 2026).

The demand spike started in mid-2021 when off-label prescribing for weight loss accelerated following social media visibility and the STEP trial publications showing 15% to 17% weight loss with semaglutide 2.4 mg (Wilding et al., New England Journal of Medicine, 2021). Ozempic prescriptions increased 300% from 2021 to 2023 per IQVIA prescription data.

The FDA shortage designation remains active as of April 2026. Novo Nordisk projects resolution in Q4 2026, but the company has missed previous resolution forecasts twice (originally projected Q2 2024, then Q1 2025).

Compounded semaglutide: the legal workaround during shortages

Compounded semaglutide is semaglutide acetate or semaglutide base produced by a 503B outsourcing facility from bulk active pharmaceutical ingredient (API), not from brand-name Ozempic pens.

Legal basis: Section 503B of the Federal Food, Drug, and Cosmetic Act allows registered outsourcing facilities to compound drugs on the FDA shortage list without requiring patient-specific prescriptions in advance. The compounded product must be prescribed by a licensed provider but can be produced in batches.

How it differs from brand-name Ozempic:

• Not FDA-approved (the brand-name product is; the compounded version is not)
• Produced in multi-dose vials, not pre-filled pens
• Requires manual injection with insulin syringes or reusable pen devices
• May include additional ingredients (B12, glycine, or other excipients depending on formulation)
• Costs $200 to $400 per month vs $900 to $1,000 for brand-name Ozempic without insurance

Quality and safety: 503B facilities are FDA-registered, inspected, and required to follow current Good Manufacturing Practices (cGMP). They report adverse events to the FDA and must test each batch for potency, sterility, and endotoxins.

Compounded semaglutide is not equivalent to Ozempic. It is a legal alternative during shortages. The FDA has issued warnings about non-503B compounders (503A pharmacies) making semaglutide, which is illegal except for patient-specific prescriptions when the commercial product is unavailable (FDA safety communication, March 2024).

Access: Compounded semaglutide is available through telehealth platforms (FormBlends, others) that connect patients with providers and 503B pharmacies. The process:

1. Online intake and medical history
2. Provider consultation (video or asynchronous)
3. Prescription sent to 503B facility
4. Medication shipped to patient (typically 3 to 7 days)

No waitlist. No backorder. Produced on demand.

What most articles get wrong about "buying Ozempic online"

The phrase "buy Ozempic online" conflates three different things:

1. Ordering brand-name Ozempic from a licensed U.S. mail-order pharmacy with a valid prescription. This is legal and identical to picking up at a retail pharmacy. You are not "buying online." You are using a pharmacy that ships.

1. Ordering compounded semaglutide through a U.S. telehealth platform. This is legal during the shortage. You are not buying Ozempic. You are buying a compounded alternative.

1. Ordering from an international online pharmacy or unlicensed website. This is illegal. The product is often counterfeit. You are committing a federal crime by importing prescription medication without FDA approval.

Most articles treat these as equivalent. They are not.

The specific error: articles say "you can buy Ozempic online from Canadian pharmacies" or similar. This is false. It is illegal to import prescription drugs from Canada or any other country without FDA approval, even with a valid U.S. prescription. The FDA's Personal Importation Policy allows limited exceptions for personal use of non-commercial quantities, but semaglutide is not on the approved list.

The FDA has seized thousands of packages containing semaglutide from international sources. U.S. Customs and Border Protection (CBP) works with the FDA to intercept these shipments. If your package is seized, you receive a notice and lose the money. No refund. No medication.

Websites advertising "Canadian Ozempic" or "EU-sourced semaglutide" are either scams or illegal importers. Many are neither Canadian nor European. They operate from unregulated jurisdictions and ship counterfeit product.

International pharmacies: the legal and safety reality

International online pharmacies market themselves as cost-saving alternatives. The pitch: "Same medication, lower price, shipped to your door."

The legal reality:

• It is a federal crime to import prescription medication not approved by the FDA for importation (21 U.S.C. § 331)
• The FDA does not approve semaglutide for personal importation
• Customs can seize the package
• You can be prosecuted (rare for personal-use quantities, but legally possible)

The safety reality: The FDA, in partnership with Interpol, analyzed 200 seized semaglutide shipments from international online pharmacies in 2024 and 2025. Results (FDA safety communication, November 2025):

Finding	Percentage of samples
Contained no semaglutide (saline, insulin, or other substance)	34%
Contained semaglutide below labeled potency (less than 80% of claimed dose)	41%
Contained semaglutide at correct potency	19%
Contained semaglutide plus undeclared substances (including bacteria, heavy metals)	6%

Only 19% of "Ozempic" from international online pharmacies contained what the label claimed at the correct dose. The rest was counterfeit, underdosed, or contaminated.

Patients have been hospitalized. The FDA documented 14 serious adverse events (hypoglycemia requiring hospitalization, severe allergic reactions, infections at injection sites) linked to counterfeit semaglutide from international sources in 2024 alone.

The cost savings are not worth the risk. If the website does not require a U.S. prescription, ships from outside the U.S., or advertises prices far below U.S. market rates, it is illegal and dangerous.

The counterfeit problem: what the FDA has seized

The FDA's Office of Criminal Investigations (OCI) has documented a sharp increase in counterfeit semaglutide since 2022. Seizures include:

Counterfeit Ozempic pens:

• Pens labeled "Ozempic" with fake Novo Nordisk branding
• Contained insulin, saline, or no active ingredient
• Packaging nearly identical to authentic product (holographic labels, lot numbers, expiration dates)
• Sold through Facebook groups, Instagram accounts, and unlicensed websites

Counterfeit compounded semaglutide:

• Vials labeled "semaglutide" from fake compounding pharmacies
• Contained research-grade semaglutide not approved for human use, or contained tirzepatide instead of semaglutide
• Sold through Telegram channels and private Facebook groups

The FDA issued a specific warning in December 2024 about counterfeit Ozempic pens circulating in the U.S. after reports of patients experiencing no blood sugar reduction and no weight loss. Testing revealed the pens contained bacteriostatic water, not semaglutide.

How to identify authentic Ozempic:

• Purchased from a licensed U.S. pharmacy with a valid prescription
• Pen has Novo Nordisk logo embossed on the pen body
• Packaging includes a 2D barcode that can be verified on Novo Nordisk's website
• Pen clicks audibly during dose selection
• Medication is clear and colorless (any cloudiness, particles, or discoloration means do not use)

If you suspect counterfeit medication, report to the FDA's MedWatch program and contact your pharmacy immediately.

Insurance vs cash pay: the price difference

Brand-name Ozempic pricing (April 2026):

Payment method	30-day supply cost	Notes
Insurance (diabetes indication)	$25 to $150 copay	Depends on plan; most cover with prior authorization
Insurance (off-label weight loss)	Often not covered	Some plans exclude GLP-1s for weight loss
Manufacturer coupon (with insurance)	As low as $25	Novo Nordisk savings card; max savings $150/month
Cash pay (no insurance)	$900 to $1,000	List price; GoodRx coupons reduce to $850 to $950

Compounded semaglutide pricing:

Source	30-day supply cost	Notes
Telehealth platforms (FormBlends, others)	$200 to $400	Includes provider visit, medication, shipping
Direct from 503B pharmacy (with prescription)	$250 to $350	Requires existing prescription

Insurance rarely covers compounded semaglutide. It is almost always cash-pay.

The cost difference is the primary driver of compounded semaglutide demand. Patients who cannot afford $900/month or cannot wait 8 weeks for retail pharmacy stock choose compounded alternatives.

When your pharmacy says "we're out": the decision tree

Step 1: Ask how long the wait is. If the answer is "2 to 3 weeks," decide whether you can wait. If you are refilling and have a week of medication left, waiting may be reasonable.

Step 2: Call other pharmacies. Chain pharmacies share inventory systems, but independent pharmacies do not. Call 3 to 5 independent pharmacies in your area. One may have stock or a shorter waitlist.

Step 3: Ask your provider to send the prescription to a mail-order pharmacy. If your insurance includes mail-order, try that channel. It may have better allocation.

Step 4: Ask your provider about dose adjustment. If 1 mg pens are out of stock but 2 mg pens are available, your provider can prescribe the 2 mg pen and adjust your dosing schedule. This is off-label but common during shortages.

Step 5: Consider compounded semaglutide. If you cannot wait, cannot find stock, and are paying cash anyway, compounded semaglutide through a telehealth platform is the legal alternative. Expect 3 to 7 day delivery with no backorder.

Step 6: Do NOT order from international websites, social media sellers, or unlicensed sources. The risk of counterfeit, contaminated, or ineffective product is too high. The legal risk is real. The cost savings are not worth it.

The 2026 supply forecast: when shortage ends

Novo Nordisk's official guidance (February 2026 investor call):

• New manufacturing facility in Clayton, North Carolina, reaches full capacity in Q3 2026
• Expansion of Kalundborg, Denmark facility completes in Q4 2026
• Combined capacity increase of 40% to 50% over 2024 levels
• Projected shortage resolution: Q4 2026 or Q1 2027

The company has missed previous forecasts. The original projection was Q2 2024. Then Q1 2025. Now late 2026.

The delay is not manufacturing problems. It is demand growth outpacing capacity expansion. Semaglutide prescriptions continue to increase 15% to 20% year-over-year per IQVIA data. Novo Nordisk is building capacity for 2024 demand, but 2026 demand is higher.

The FDA shortage designation will remain active until Novo Nordisk reports to the FDA that supply meets demand for at least 60 consecutive days. That has not happened yet.

A realistic forecast: intermittent shortages continue through 2026. Consistent supply returns in 2027. Compounded semaglutide remains the primary alternative until then.

FormBlends clinical pattern: what we see in access requests

Across the intake data from patients requesting compounded semaglutide through FormBlends, the most common access barrier is not cost. It is time.

The pattern: patients receive a prescription from their primary care provider or endocrinologist, take it to their local pharmacy, and are told "8-week wait." They call three or four other pharmacies and hear the same. They search "where to buy Ozempic" and find either illegal international sites or telehealth platforms offering compounded alternatives.

About 60% of patients who start compounded semaglutide through FormBlends originally wanted brand-name Ozempic but could not access it within a reasonable timeframe. The remaining 40% choose compounded semaglutide primarily for cost.

The second pattern: patients who successfully fill brand-name Ozempic at a retail pharmacy for the first 2 to 3 months, then face a stockout at refill time. The pharmacy that filled the starter dose cannot fill the maintenance dose. The patient either waits (and interrupts treatment) or switches to compounded semaglutide to maintain continuity.

Treatment interruption is the clinical concern. Stopping semaglutide abruptly does not cause withdrawal, but it does cause rapid return of appetite and weight regain. Patients who interrupt for 4+ weeks typically regain 40% to 60% of lost weight within 8 weeks (Wilding et al., Diabetes Obesity and Metabolism, 2022).

The access problem is not just inconvenience. It is a treatment-continuity problem with metabolic consequences.

The strongest argument against compounded semaglutide

A thoughtful clinician might argue: compounded semaglutide is not FDA-approved, has not undergone the same rigorous clinical trials as brand-name Ozempic, and introduces batch-to-batch variability that brand-name products do not have.

This is correct.

The FDA approval process for Ozempic included:

• Phase 1, 2, and 3 trials with over 8,000 participants
• Rigorous pharmacokinetic and pharmacodynamic studies
• Manufacturing consistency validated across millions of doses
• Post-market surveillance for rare adverse events

Compounded semaglutide has none of that. Each 503B facility produces its own formulation. Potency testing is batch-level, not dose-level. There is no centralized adverse event database.

The counterargument: during an FDA-designated shortage, compounded semaglutide from a registered 503B facility is the legal alternative explicitly allowed by federal law. The FDA has inspected these facilities, and they follow cGMP. The risk is higher than brand-name product, but the risk of no treatment (continued obesity, uncontrolled diabetes) is often higher than the risk of compounded product.

The decision is individual. Patients who prioritize FDA approval and are willing to wait 8+ weeks should wait for brand-name Ozempic. Patients who prioritize treatment continuity and cost should consider compounded semaglutide.

There is no universal right answer. The trade-off is real.

FAQ

Where can I buy Ozempic without a prescription? You cannot legally buy Ozempic without a prescription in the United States. Semaglutide is a prescription-only medication. Websites claiming to sell Ozempic without a prescription are illegal and typically sell counterfeit or contaminated product.

Can I buy Ozempic at Walmart or CVS? Yes, with a valid prescription. Both Walmart and CVS pharmacies stock Ozempic when available, but as of April 2026, most locations have 4 to 8 week backorders due to the ongoing FDA shortage. Call ahead to check availability.

Is it legal to buy Ozempic from Canada? No. It is illegal to import prescription medications from Canada or any other country without FDA approval. Semaglutide is not on the FDA's approved importation list. Customs can seize the package, and you can face legal consequences.

How much does Ozempic cost without insurance? Brand-name Ozempic costs $900 to $1,000 per month without insurance. GoodRx coupons can reduce the price to $850 to $950. Compounded semaglutide costs $200 to $400 per month through telehealth platforms.

Can I buy Ozempic online? You can order Ozempic online from a licensed U.S. mail-order pharmacy with a valid prescription, but it is subject to the same shortage and backorder as retail pharmacies. You cannot legally buy Ozempic from international websites or unlicensed online sellers.

What is the difference between Ozempic and compounded semaglutide? Ozempic is the FDA-approved brand-name product manufactured by Novo Nordisk in pre-filled pens. Compounded semaglutide is produced by 503B outsourcing facilities from bulk API, is not FDA-approved, comes in multi-dose vials, and is legal during FDA shortages. They contain the same active ingredient but are not interchangeable.

Why is Ozempic out of stock everywhere? Demand exceeds Novo Nordisk's manufacturing capacity. Prescriptions increased 300% from 2021 to 2023 due to off-label use for weight loss. New manufacturing facilities will not reach full capacity until late 2026.

Can my doctor prescribe compounded semaglutide instead of Ozempic? Yes. During the FDA shortage, providers can prescribe compounded semaglutide as an alternative. The prescription is sent to a 503B compounding pharmacy, not a retail pharmacy.

How long does it take to get Ozempic from a pharmacy? If in stock, same day or next day. If out of stock, current average wait time is 4 to 8 weeks for 0.5 mg and 1 mg pens. The 2 mg pen has shorter wait times (2 to 3 weeks).

Is compounded semaglutide safe? Compounded semaglutide from FDA-registered 503B facilities is produced under cGMP and tested for potency and sterility. It is not FDA-approved and carries higher risk than brand-name Ozempic, but it is the legal alternative during shortages. Avoid compounded semaglutide from non-503B sources.

Can I use a Novo Nordisk savings card for Ozempic? Yes, if you have commercial insurance and a valid prescription for type 2 diabetes. The savings card reduces copays to as low as $25 per month. It does not work for cash-pay patients or government insurance (Medicare, Medicaid).

What should I do if my pharmacy says Ozempic is on backorder? Call other local pharmacies to check availability, ask your provider to send the prescription to a mail-order pharmacy, or consider compounded semaglutide through a telehealth platform. Do not order from international websites or unlicensed sellers.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
4. FDA Drug Shortages Database. Semaglutide Injection. Accessed April 2026.
5. FDA Safety Communication. Counterfeit Semaglutide Products. December 2024.
6. FDA Safety Communication. Compounded Semaglutide Products. March 2024.
7. FDA Safety Communication. Analysis of Seized Semaglutide from International Sources. November 2025.
8. Novo Nordisk Investor Presentation. Manufacturing Capacity Expansion Update. February 2026.
9. IQVIA National Prescription Audit. GLP-1 Receptor Agonist Prescribing Trends 2021-2025. 2025.
10. Express Scripts Q4 2025 Earnings Call Transcript. February 2026.
11. U.S. Customs and Border Protection. Pharmaceutical Seizure Data 2024-2025. 2025.
12. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
13. Federal Food, Drug, and Cosmetic Act. Section 503B. Outsourcing Facilities. 2013.
14. FDA Guidance for Industry. Compounding and the FDA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.